ASH 2022 | Venetoclax-based quadruplet therapy with trametinib for patients with RAS-mutated AML and MDS
Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the use of a venetoclax-based quadruplet regimen for patients with RAS-mutated acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Whilst all patients responded to the regimen, response durations were short and all patients relapsed, therefore suggesting that MEK inhibition has limited efficacy in this setting. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie: Consultancy, Honoraria, Other: Travel Expenses; Astellas: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Other: Travel Expenses; Pfizer: Consultancy
